Wire · opportunities
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 October 2026 · Fusion42 review
The U.S. FDA approved an expanded indication for Lilly's Jaypirca (pirtobrutinib), the first-and-only non-covalent BTK inhibitor, to treat adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without the 17p deletion, allowing its use as a first-line therapy based on positive BRUIN CLL-313 trial results.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 2 Oct 2026 and 5 Oct 2026.
◆ ◆ The Wire takeaway
You now have a new FDA-approved treatment option for first-line CLL/SLL patients without 17p deletion that delays disease progression better than chemoimmunotherapy. This shifts treatment norms and opens patient access early in their therapy journey.
◆ Coverage
3 sources · first reported 2 Oct 2026 · latest 5 Oct 2026
◆ Related on Wire
◆ Topics